What the superinvestors bought and sold in 2024 Q3
2024 Q3
134 of 137 filedThe quarter at a glance
79 of 133 managers were net sellers. Setting price aside, they took $60.8B out, led by Information Technology (−$33.1B), while adding to Materials (+$2.2B). DIS was the most widely bought stock (10 bought, 3 sold); META the most widely sold (23 sold, 7 bought).
Net buyers
47 of 133 managers
79 sold more than they bought · 7 about even
Net bought
−$60.8B
Price moves taken out; prices alone moved the book +$93.2B.
Positions opened
626
673 closed out. IPOs, spin-offs and mergers left out.
Combined book, last quarter
+7.5%
SPY +5.4%,
2.1 pts ahead.
Price only.
Most bought and sold
Ranked by how many managers bought minus how many sold, with price moves taken out. Open a stock to see who.
Most bought
-
1 DIS Disney Walt Co. 10 bought · 3 sold +$199M
Bought by
- Valueact Capital - Valueact Holdings added 17.1% → 18.2%
- Lindsell Train added 11.5% → 11.8%
- Kahn Brothers Group added 3.7% → 6.7%
- Harry Burn - Sound Shore Management added 2.1% → 3.0%
- Farallon Capital Management added 1.7% → 2.7%
- Sarah Ketterer - Causeway Capital Management added 2.7% → 2.6%
- Robert Olstein - Olstein Capital Management added 2.1% → 2.6%
- Hillman Capital Management added 1.9% → 2.2%
and 2 more
Sold by
- Nelson Peltz - Trian Fund Management closed was 6.4%
- Don Yacktman - Yacktman Asset Management cut 1.5% → 1.5%
- Mairs & Power cut 0.34% → 0.31%
-
2 FLUT Flutter Entmt PLC 10 bought · 4 sold +$2.1B
Bought by
- Tom Bancroft - Makaira Partners opened 6.1% of book
- John Armitage - Egerton Capital (UK) added 1.9% → 4.3%
- William Von Mueffling - Cantillon Capital Management added 0.07% → 3.5%
- Chase Coleman - Tiger Global Management opened 3.4% of book
- Andreas Halvorsen - Viking Global Investors opened 2.2% of book
- Ryan Packard - Hiddenite Capital Partners opened 1.6% of book
- Dan Loeb - Third Point opened 1.6% of book
- Lee Ainslie - Maverick Capital added 0.09% → 1.0%
and 2 more
Sold by
- Stanley Druckenmiller - Duquesne Family Office cut 2.1% → 2.1%
- Dan Sundheim - D1 Capital Partners closed was 1.3%
- Valueact Capital - Valueact Holdings closed was 1.3%
- Farallon Capital Management cut 0.17% → 0.06%
-
3 SIRI Sirius Xm Holdings Inc. 6 bought · 0 sold +$2.1B
Bought by
- Wallace Weitz - Weitz Investment Management opened 1.5% of book
- Warren Buffett - Berkshire Hathaway added 0.13% → 0.93%
- Francis Chou - Chou Associates Management opened 0.35% of book
- Steven Check - Check Capital Management opened 0.12% of book
- Murray Stahl - Horizon Kinetics Asset Management opened 0.02% of book
- Lee Ainslie - Maverick Capital opened 0.02% of book
Sold by
No manager sold.
-
4 APD Air Products & Chemicals, Inc. 6 bought · 0 sold +$2.1B
Bought by
- Sachem Head Capital Management opened 8.6% of book
- Dodge & Cox added <0.01% → 1.1%
- Thomas Gayner - Markel Group added 0.10% → 0.14%
- Corvex Management opened 0.10% of book
- Jensen Investment Management added 0.02% → 0.03%
- Mairs & Power opened <0.01% of book
Sold by
No manager sold.
-
5 GPN Global Pmts Inc. 6 bought · 0 sold +$409M
Bought by
- Estuary Capital Management added 9.0% → 10.4%
- Glenview Capital Management added 5.9% → 8.2%
- Wallace Weitz - Weitz Investment Management added 2.7% → 3.1%
- Ryan Packard - Hiddenite Capital Partners opened 1.1% of book
- George Soros - Soros Fund Management opened 0.68% of book
- Bill Nygren / Oakmark - Harris Associates L P added 0.47% → 0.67%
Sold by
No manager sold.
-
6 WCC Wesco Intl Inc. 8 bought · 2 sold +$85M
Bought by
- Alex Roepers - Atlantic Investment Management added 12.0% → 15.9%
- Seth Klarman - Baupost Group added 3.5% → 6.0%
- Robert Olstein - Olstein Capital Management added 1.4% → 1.6%
- Third Avenue Management added 0.13% → 0.40%
- Christopher Davis - Davis Selected Advisers added 0.18% → 0.24%
- Richard Pzena - Pzena Investment Management added 0.08% → 0.12%
- Lee Ainslie - Maverick Capital added 0.03% → 0.04%
- First Eagle Investment Management added <0.01% → <0.01%
Sold by
- Lyrical Asset Management cut 1.9% → 1.7%
- Glenview Capital Management cut 1.2% → 0.89%
-
7 PDD Pdd Holdings Inc. 9 bought · 4 sold +$1.2B
Bought by
- David Tepper - Appaloosa added 4.2% → 10.6%
- Marc Stad - Dragoneer Investment Group added 6.7% → 8.8%
- Ram Parameswaran - Octahedron Capital Management opened 5.9% of book
- Duan Yongping - H&H International Investment added 0.08% → 3.2%
- Alex Sacerdote - Whale Rock Capital Management added 2.3% → 2.9%
- Philippe Laffont - Coatue Management added 0.16% → 1.3%
- Nehal Chopra - Ratan Capital Management opened 0.62% of book
- Howard Marks - Oaktree Capital Management opened 0.61% of book
and 1 more
Sold by
- Brad Gerstner - Altimeter Capital Management closed was 3.4%
- Dan Sundheim - D1 Capital Partners cut 1.0% → 1.00%
- Ron Baron - Bamco Inc. (Baron Capital) cut 0.27% → 0.07%
- Lee Ainslie - Maverick Capital closed was 0.01%
-
8 DG Dollar Gen Corp. New 5 bought · 0 sold +$952M
Bought by
- Christopher Bloomstran - Semper Augustus Investments Group added 10.4% → 12.3%
- Estuary Capital Management added 10.6% → 7.8%
- Seth Klarman - Baupost Group opened 5.5% of book
- Richard Pzena - Pzena Investment Management added 0.86% → 2.8%
- Thomas Gayner - Markel Group added 0.91% → 0.56%
Sold by
No manager sold.
-
9 SBUX Starbucks Corp. 9 bought · 4 sold +$465M
Bought by
- Lee Ainslie - Maverick Capital added 2.1% → 3.6%
- Nehal Chopra - Ratan Capital Management opened 3.3% of book
- Stephen Mandel - Lone Pine Capital opened 2.9% of book
- David Katz - Matrix Asset Advisors added 1.8% → 2.3%
- Dan Sundheim - D1 Capital Partners opened 2.2% of book
- Davidson Kempner Capital Management opened 1.1% of book
- Andreas Halvorsen - Viking Global Investors opened 0.59% of book
- Thomas Gayner - Markel Group added 0.44% → 0.53%
and 1 more
Sold by
- Jensen Investment Management cut 2.3% → 1.1%
- Vulcan Value Partners closed was 0.77%
- Gavin Baker - Atreides Management closed was 0.71%
- Mairs & Power closed was <0.01%
-
10 WDC Western Digital Corp. 6 bought · 1 sold +$178M
Bought by
- Sachem Head Capital Management added 4.4% → 7.3%
- Davidson Kempner Capital Management added 2.2% → 2.9%
- Paul Singer - Elliott Investment Management added 0.52% → 0.80%
- Glenview Capital Management opened 0.57% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.17% of book
- Lee Ainslie - Maverick Capital opened 0.11% of book
Sold by
- Nehal Chopra - Ratan Capital Management closed was 1.8%
Not counted as buying: 143 IPOs, spin-offs and new listings.
Most sold
-
1 META Meta Platforms Inc. 7 bought · 23 sold −$1B
Sold by
- Robert Vinall - Rv Capital AG cut 22.2% → 17.7%
- Pat Dorsey - Dorsey Asset Management cut 14.4% → 14.4%
- Christopher Davis - Davis Selected Advisers cut 9.0% → 8.7%
- Philippe Laffont - Coatue Management cut 8.2% → 7.9%
- David Tepper - Appaloosa cut 7.6% → 5.3%
- John Armitage - Egerton Capital (UK) cut 6.8% → 5.9%
- First Pacific Advisors cut 6.5% → 7.2%
- Dan Loeb - Third Point cut 6.3% → 4.2%
and 15 more
Bought by
- Mala Gaonkar - Surgocap Partners opened 8.7% of book
- Stephen Mandel - Lone Pine Capital added 5.7% → 8.1%
- Francois Rochon - Giverny Capital added 6.3% → 6.7%
- Nehal Chopra - Ratan Capital Management added 4.4% → 4.8%
- Valueact Capital - Valueact Holdings opened 3.1% of book
- Davidson Kempner Capital Management added 1.7% → 2.9%
- Dan Sundheim - D1 Capital Partners opened 2.8% of book
-
2 BRK.B / BRK.A Berkshire Hathaway 0 bought · 13 sold −$1.7B
Sold by
- Tweedy, Browne Co. cut 21.2% → 21.7%
- Gates Foundation Trust cut 21.0% → 22.6%
- Thomas Russo - Gardner Russo & Quinn cut 19.6% → 20.9%
- Steven Check - Check Capital Management cut 17.1% → 16.4%
- Duan Yongping - H&H International Investment cut 9.5% → 10.5%
- Christopher Davis - Davis Selected Advisers cut 8.4% → 8.2%
- Arnold Van Den Berg - Van Den Berg Management I cut 6.6% → 6.1%
- Torray Investment Partners cut 3.9% → 3.7%
and 5 more
Bought by
No manager bought.
-
3 GOOG / GOOGL Alphabet 12 bought · 24 sold −$2.2B
Sold by
- Tweedy, Browne Co. cut 17.5% → 13.9%
- Altarock Partners cut 15.0% → 10.9%
- Ram Parameswaran - Octahedron Capital Management cut 14.3% → 2.7%
- First Pacific Advisors cut 13.0% → 10.7%
- Ruane, Cunniff & Goldfarb cut 12.1% → 10.7%
- Thomas Russo - Gardner Russo & Quinn cut 12.1% → 10.3%
- Polen Capital Management cut 8.6% → 6.1%
- Alex Sacerdote - Whale Rock Capital Management cut 7.7% → 5.6%
and 16 more
Bought by
- Grant Wonders - Voyager Global Management added 13.8% → 19.0%
- Triple Frond Partners added 15.5% → 18.1%
- Eric Mandelblatt - Soroban Capital Partners added 15.0% → 15.4%
- Seth Klarman - Baupost Group added 5.4% → 7.0%
- Corvex Management added 4.3% → 4.1%
- Philippe Laffont - Coatue Management added 2.4% → 2.7%
- Sarah Ketterer - Causeway Capital Management added 2.4% → 2.3%
- Farallon Capital Management added 1.6% → 2.0%
and 4 more
-
4 UNH Unitedhealth Group Inc. 5 bought · 14 sold −$1B
Sold by
- Jensen Investment Management cut 4.0% → 3.6%
- Stephen Mandel - Lone Pine Capital cut 3.9% → 3.6%
- Farallon Capital Management cut 3.9% → 3.1%
- Polen Capital Management cut 2.9% → 3.0%
- Arnold Van Den Berg - Van Den Berg Management I cut 1.5% → 1.6%
- David Tepper - Appaloosa cut 1.5% → 1.5%
- Robert Olstein - Olstein Capital Management cut 1.5% → 1.2%
- Murphy Pohlad - Murphy Pohlad Asset Management cut 1.3% → 0.97%
and 6 more
Bought by
- Mairs & Power added 4.2% → 4.9%
- David Witzke - Avidity Partners Management opened 2.6% of book
- Chris James - Meritage Group opened 0.41% of book
- Thomas Gayner - Markel Group added 0.10% → 0.13%
- Bill Nygren / Oakmark - Harris Associates L P added <0.01% → <0.01%
-
5 GS The Goldman Sachs Group, Inc. 0 bought · 9 sold −$225M
Sold by
- David Katz - Matrix Asset Advisors cut 2.2% → 2.0%
- Robert Olstein - Olstein Capital Management cut 0.97% → 0.78%
- John Rogers - Ariel Investments cut 0.89% → 0.77%
- Richard Pzena - Pzena Investment Management cut 0.70% → 0.64%
- Don Yacktman - Yacktman Asset Management cut 0.67% → 0.65%
- Bill Nygren / Oakmark - Harris Associates L P cut 0.57% → 0.32%
- Greenhaven Associates cut 0.34% → 0.05%
- George Soros - Soros Fund Management cut 0.27% → 0.14%
and 1 more
Bought by
No manager bought.
-
6 AAPL Apple Inc. 7 bought · 15 sold −$24.8B
Sold by
- Duan Yongping - H&H International Investment cut 81.0% → 74.3%
- Warren Buffett - Berkshire Hathaway cut 30.1% → 26.2%
- Jensen Investment Management cut 6.7% → 7.1%
- Li Lu - Himalaya Capital Management cut 6.2% → 3.0%
- Dan Loeb - Third Point cut 4.7% → 2.9%
- Glen Kacher - Light Street Capital Management cut 3.7% → 3.6%
- Alex Sacerdote - Whale Rock Capital Management closed was 1.6%
- Brad Gerstner - Altimeter Capital Management closed was 0.85%
and 7 more
Bought by
- Mala Gaonkar - Surgocap Partners added 5.9% → 8.3%
- Andreas Halvorsen - Viking Global Investors added 3.7% → 4.1%
- Polen Capital Management opened 4.1% of book
- Gavin Baker - Atreides Management added 2.2% → 2.5%
- John Armitage - Egerton Capital (UK) opened 0.47% of book
- Sarah Ketterer - Causeway Capital Management opened <0.01% of book
- Cathie Wood - Ark Investment Management opened <0.01% of book
-
7 BKNG Booking Holdings, Inc. 0 bought · 8 sold −$545M
Sold by
- Ako Capital cut 4.7% → 4.1%
- John Armitage - Egerton Capital (UK) cut 4.4% → 2.7%
- Henry Ellenbogen - Durable Capital Partners cut 4.2% → 3.8%
- Stephen Mandel - Lone Pine Capital cut 3.4% → 2.4%
- Ben Jacobs - Anomaly Capital Management closed was 3.2%
- Don Yacktman - Yacktman Asset Management cut 1.4% → 1.5%
- George Soros - Soros Fund Management cut 1.2% → 0.37%
- Bill Nygren / Oakmark - Harris Associates L P cut <0.01% → <0.01%
Bought by
No manager bought.
-
8 MU Micron Technology Inc. 2 bought · 10 sold −$202M
Sold by
- Ben Hoskin - Value Aligned Research Advisors closed was 3.7%
- Gavin Baker - Atreides Management cut 3.1% → 1.0%
- David Tepper - Appaloosa cut 2.5% → 1.6%
- Lee Ainslie - Maverick Capital cut 1.6% → 0.08%
- Alex Sacerdote - Whale Rock Capital Management closed was 0.83%
- Dan Loeb - Third Point closed was 0.41%
- Spencer Waxman - Shannon River Fund Management closed was 0.22%
- George Soros - Soros Fund Management closed was 0.07%
and 2 more
Bought by
- Prem Watsa - Fairfax Financial Holdings added 0.45% → 0.75%
- Glen Kacher - Light Street Capital Management added 0.05% → 0.05%
-
9 MSFT Microsoft Corp. 12 bought · 19 sold −$4.1B
Sold by
- Gates Foundation Trust cut 32.7% → 27.6%
- Terry Smith - Fundsmith cut 13.0% → 11.7%
- Josh Tarasoff - Greenlea Lane Capital Management cut 10.9% → 5.1%
- Brad Gerstner - Altimeter Capital Management cut 10.8% → 10.1%
- Polen Capital Management cut 10.1% → 7.8%
- David Tepper - Appaloosa cut 8.6% → 6.2%
- Dan Loeb - Third Point cut 8.1% → 5.0%
- Jensen Investment Management cut 8.1% → 7.6%
and 11 more
Bought by
- Eric Mandelblatt - Soroban Capital Partners added 21.3% → 20.1%
- Triple Frond Partners added 12.0% → 14.0%
- Chris Hohn - Tci Fund Management added 11.5% → 11.7%
- Grant Wonders - Voyager Global Management added 5.0% → 8.4%
- Nehal Chopra - Ratan Capital Management added 5.2% → 7.9%
- John Armitage - Egerton Capital (UK) added 6.7% → 7.5%
- Ako Capital added 7.4% → 7.1%
- Farallon Capital Management added 2.5% → 3.1%
and 4 more
-
10 CHTR Charter Communications, Inc. 0 bought · 7 sold −$1B
Sold by
- Triple Frond Partners cut 22.0% → 11.4%
- Tom Bancroft - Makaira Partners cut 14.5% → 14.9%
- Grant Wonders - Voyager Global Management cut 10.0% → 10.1%
- Bill Nygren / Oakmark - Harris Associates L P cut 3.2% → 2.2%
- Wallace Weitz - Weitz Investment Management cut 2.2% → 2.2%
- Andreas Halvorsen - Viking Global Investors closed was 0.50%
- Warren Buffett - Berkshire Hathaway cut 0.41% → 0.34%
Bought by
No manager bought.
Not counted as selling: 141 mergers and delistings.
Opened and closed
New positions started from zero, and positions sold down to zero. IPOs, spin-offs and mergers are left out.
Opened by the most managers
-
FLUT Flutter Entmt PLC 6 managers avg 2.6% of book · Tom Bancroft - Makaira Partners, Chase Coleman - Tiger Global Management and 4 more
Opened by
- Tom Bancroft - Makaira Partners opened 6.1% of book
- Chase Coleman - Tiger Global Management opened 3.4% of book
- Andreas Halvorsen - Viking Global Investors opened 2.2% of book
- Ryan Packard - Hiddenite Capital Partners opened 1.6% of book
- Dan Loeb - Third Point opened 1.6% of book
- Senator Investment Group opened 0.73% of book
-
TSM Taiwan Semiconductor Mfg Ltd 6 managers avg 2.4% of book · Estuary Capital Management, Nehal Chopra - Ratan Capital Management and 4 more
Opened by
- Estuary Capital Management opened 8.0% of book
- Nehal Chopra - Ratan Capital Management opened 2.4% of book
- Eric Mandelblatt - Soroban Capital Partners opened 2.3% of book
- Brad Gerstner - Altimeter Capital Management opened 1.3% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.34% of book
- Hillman Capital Management opened 0.10% of book
-
SBUX Starbucks Corp. 6 managers avg 1.7% of book · Nehal Chopra - Ratan Capital Management, Stephen Mandel - Lone Pine Capital and 4 more
Opened by
- Nehal Chopra - Ratan Capital Management opened 3.3% of book
- Stephen Mandel - Lone Pine Capital opened 2.9% of book
- Dan Sundheim - D1 Capital Partners opened 2.2% of book
- Davidson Kempner Capital Management opened 1.1% of book
- Andreas Halvorsen - Viking Global Investors opened 0.59% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.17% of book
-
AVGO Broadcom Inc. 5 managers avg 1.4% of book · Nehal Chopra - Ratan Capital Management, Stanley Druckenmiller - Duquesne Family Office and 3 more
Opened by
- Nehal Chopra - Ratan Capital Management opened 3.1% of book
- Stanley Druckenmiller - Duquesne Family Office opened 1.4% of book
- Lee Ainslie - Maverick Capital opened 1.2% of book
- Brad Gerstner - Altimeter Capital Management opened 1.0% of book
- Davidson Kempner Capital Management opened 0.35% of book
-
SIRI Sirius Xm Holdings Inc. 5 managers avg 0.40% of book · Wallace Weitz - Weitz Investment Management, Francis Chou - Chou Associates Management and 3 more
Opened by
- Wallace Weitz - Weitz Investment Management opened 1.5% of book
- Francis Chou - Chou Associates Management opened 0.35% of book
- Steven Check - Check Capital Management opened 0.12% of book
- Murray Stahl - Horizon Kinetics Asset Management opened 0.02% of book
- Lee Ainslie - Maverick Capital opened 0.02% of book
-
ADSK Autodesk Inc. 4 managers avg 3.0% of book · Starboard Value, Andreas Halvorsen - Viking Global Investors and 2 more
Opened by
- Starboard Value opened 10.8% of book
- Andreas Halvorsen - Viking Global Investors opened 0.77% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.34% of book
- Mairs & Power opened <0.01% of book
-
GTLB Gitlab Inc. 4 managers avg 1.5% of book · Glen Kacher - Light Street Capital Management, Ryan Packard - Hiddenite Capital Partners and 2 more
Opened by
- Glen Kacher - Light Street Capital Management opened 4.5% of book
- Ryan Packard - Hiddenite Capital Partners opened 0.84% of book
- Gavin Baker - Atreides Management opened 0.65% of book
- Cathie Wood - Ark Investment Management opened 0.12% of book
-
AAPL Apple Inc. 4 managers avg 1.1% of book · Polen Capital Management, John Armitage - Egerton Capital (UK) and 2 more
Opened by
- Polen Capital Management opened 4.1% of book
- John Armitage - Egerton Capital (UK) opened 0.47% of book
- Sarah Ketterer - Causeway Capital Management opened <0.01% of book
- Cathie Wood - Ark Investment Management opened <0.01% of book
-
TSLA Tesla Inc. 4 managers avg 1.1% of book · Brad Gerstner - Altimeter Capital Management, Dan Loeb - Third Point and 2 more
Opened by
- Brad Gerstner - Altimeter Capital Management opened 2.6% of book
- Dan Loeb - Third Point opened 1.4% of book
- Andreas Halvorsen - Viking Global Investors opened 0.42% of book
- David Katz - Matrix Asset Advisors opened 0.02% of book
-
BNTX Biontech Se 4 managers avg 0.38% of book · David Witzke - Avidity Partners Management, Palo Alto Investors and 2 more
Opened by
- David Witzke - Avidity Partners Management opened 0.88% of book
- Palo Alto Investors opened 0.39% of book
- Nathan Fischel - Dafna Capital Management opened 0.24% of book
- Andreas Halvorsen - Viking Global Investors opened 0.02% of book
Closed out by the most managers
-
META Meta Platforms Inc. 7 managers was avg 0.91% of book · Lee Ainslie - Maverick Capital, Gavin Baker - Atreides Management and 5 more
Closed by
- Lee Ainslie - Maverick Capital closed was 2.8%
- Gavin Baker - Atreides Management closed was 1.4%
- Grant Wonders - Voyager Global Management closed was 1.1%
- Prem Watsa - Fairfax Financial Holdings closed was 0.55%
- Andreas Halvorsen - Viking Global Investors closed was 0.52%
- Chris James - Meritage Group closed was <0.01%
- Polen Capital Management closed was <0.01%
-
MU Micron Technology Inc. 7 managers was avg 0.76% of book · Ben Hoskin - Value Aligned Research Advisors, Alex Sacerdote - Whale Rock Capital Management and 5 more
Closed by
- Ben Hoskin - Value Aligned Research Advisors closed was 3.7%
- Alex Sacerdote - Whale Rock Capital Management closed was 0.83%
- Dan Loeb - Third Point closed was 0.41%
- Spencer Waxman - Shannon River Fund Management closed was 0.22%
- George Soros - Soros Fund Management closed was 0.07%
- Don Yacktman - Yacktman Asset Management closed was 0.04%
- Ron Baron - Bamco Inc. (Baron Capital) closed was <0.01%
-
AAPL Apple Inc. 5 managers was avg 0.71% of book · Alex Sacerdote - Whale Rock Capital Management, Brad Gerstner - Altimeter Capital Management and 3 more
Closed by
- Alex Sacerdote - Whale Rock Capital Management closed was 1.6%
- Brad Gerstner - Altimeter Capital Management closed was 0.85%
- Davidson Kempner Capital Management closed was 0.52%
- George Soros - Soros Fund Management closed was 0.38%
- Stanley Druckenmiller - Duquesne Family Office closed was 0.18%
-
NVDA Nvidia Corporation 4 managers was avg 3.9% of book · Spencer Waxman - Shannon River Fund Management, Mala Gaonkar - Surgocap Partners and 2 more
Closed by
- Spencer Waxman - Shannon River Fund Management closed was 8.2%
- Mala Gaonkar - Surgocap Partners closed was 6.2%
- Stanley Druckenmiller - Duquesne Family Office closed was 0.91%
- Ram Parameswaran - Octahedron Capital Management closed was 0.43%
-
DELL Dell Technologies Inc. 4 managers was avg 3.0% of book · Nehal Chopra - Ratan Capital Management, Glen Kacher - Light Street Capital Management and 2 more
Closed by
- Nehal Chopra - Ratan Capital Management closed was 6.0%
- Glen Kacher - Light Street Capital Management closed was 4.0%
- Ben Jacobs - Anomaly Capital Management closed was 1.0%
- Brad Gerstner - Altimeter Capital Management closed was 1.0%
-
QCOM Qualcomm Inc. 4 managers was avg 2.3% of book · Mala Gaonkar - Surgocap Partners, Alex Sacerdote - Whale Rock Capital Management and 2 more
Closed by
- Mala Gaonkar - Surgocap Partners closed was 7.3%
- Alex Sacerdote - Whale Rock Capital Management closed was 1.9%
- Glen Kacher - Light Street Capital Management closed was 0.07%
- Lee Ainslie - Maverick Capital closed was 0.03%
-
MRVL Marvell Technology Inc. 4 managers was avg 2.0% of book · Gavin Baker - Atreides Management, Dan Sundheim - D1 Capital Partners and 2 more
Closed by
- Gavin Baker - Atreides Management closed was 5.8%
- Dan Sundheim - D1 Capital Partners closed was 1.8%
- Nehal Chopra - Ratan Capital Management closed was 0.42%
- Ron Baron - Bamco Inc. (Baron Capital) closed was 0.04%
-
AVGO Broadcom Inc. 4 managers was avg 1.5% of book · Muhlenkamp & Co., Andreas Halvorsen - Viking Global Investors and 2 more
Closed by
- Muhlenkamp & Co. closed was 4.1%
- Andreas Halvorsen - Viking Global Investors closed was 1.8%
- Spencer Waxman - Shannon River Fund Management closed was 0.18%
- George Soros - Soros Fund Management closed was 0.01%
-
INTC Intel Corp. 4 managers was avg 1.4% of book · Estuary Capital Management, James Silverman - Opaleye Management and 2 more
Closed by
- Estuary Capital Management closed was 4.3%
- James Silverman - Opaleye Management closed was 1.1%
- David Witzke - Avidity Partners Management closed was 0.16%
- Richard Pzena - Pzena Investment Management closed was <0.01%
-
APH Amphenol Corp. 4 managers was avg 1.2% of book · Brad Gerstner - Altimeter Capital Management, Philippe Laffont - Coatue Management and 2 more
Closed by
- Brad Gerstner - Altimeter Capital Management closed was 2.0%
- Philippe Laffont - Coatue Management closed was 1.6%
- Lee Ainslie - Maverick Capital closed was 1.2%
- David Katz - Matrix Asset Advisors closed was 0.02%
Where the money went
Net bought by sector, with price moves taken out. Pick a sector to see its names.
- Materials 3.3% weight · no change +$2.2B 18 bought · 14 sold
- Real Estate 2.7% weight · +0.1 pts +$477M 6 bought · 23 sold
- Consumer Discretionary 15.5% weight · +0.5 pts +$369M 36 bought · 41 sold
- Energy 3.9% weight · −0.3 pts −$208M 18 bought · 12 sold
- Utilities 1.5% weight · +0.1 pts −$269M 9 bought · 12 sold
- Industrials 9.9% weight · +0.3 pts −$871M 22 bought · 40 sold
- Communication Services 9.7% weight · −0.4 pts −$2.4B 25 bought · 43 sold
- Consumer Staples 3.3% weight · −0.2 pts −$2.8B 14 bought · 19 sold
- Health Care 12.4% weight · +0.6 pts −$3.3B 23 bought · 39 sold
- Financials 17.9% weight · no change −$17.2B 21 bought · 61 sold
- Information Technology 19.9% weight · −0.7 pts −$33.1B 40 bought · 52 sold
Health Care gained weight (+0.6 pts) even though managers sold $3.3B of it: weight follows price, not buying. Names without a sector (funds, foreign listings, private shares): −$716M.
Who moved the most
The biggest new positions, measured against each manager’s own book, and the managers that traded the most of theirs.
Biggest new bets
- King Street Capital Management opened SGRY · Surgery Partners Inc. 31.8% of book
- Jana Partners Management opened LW · Lamb Weston Hldgs Inc. 11.9% of book
- Starboard Value opened ADSK · Autodesk Inc. 10.8% of book
- Pat Dorsey - Dorsey Asset Management opened APP · Applovin Corp. 9.8% of book
- Mala Gaonkar - Surgocap Partners opened META · Meta Platforms Inc. 8.7% of book
- Sachem Head Capital Management opened APD · Air Products & Chemicals, Inc. 8.6% of book
Most active managers
- Estuary Capital Management 6 opened · 6 closed · +$111M net 87% of book traded
- Dan Sundheim - D1 Capital Partners 10 opened · 12 closed · −$1.6B net 77% of book traded
- Stanley Druckenmiller - Duquesne Family Office 30 opened · 21 closed · −$361M net 70% of book traded
- Gavin Baker - Atreides Management 6 opened · 11 closed · −$229M net 69% of book traded
- Alex Roepers - Atlantic Investment Management 0 opened · 5 closed · −$5M net 69% of book traded
- Andreas Halvorsen - Viking Global Investors 21 opened · 19 closed · −$29M net 67% of book traded
What they hold
Most owned counts managers, with the change since last quarter. Largest is the share of the combined book, each manager counting once. Highest conviction is the average position among holders, three or more.
Most owned
- 1 GOOG / GOOGL Alphabet 68 managers −3
- 2 MSFT Microsoft Corp. 60 managers −1
- 3 AMZN Amazon Com Inc. 47 managers no change
- 4 META Meta Platforms Inc. 41 managers −4
- 5 BRK.B / BRK.A Berkshire Hathaway 36 managers −1
- 6 AAPL Apple Inc. 34 managers −1
- 7 V Visa Inc. 33 managers +3
- 8 TSM Taiwan Semiconductor Mfg Ltd 30 managers +3
- 9 MA Mastercard Inc. 28 managers no change
- 10 UNH Unitedhealth Group Inc. 27 managers −2
Largest
- 1 GOOG / GOOGL Alphabet 3.0% held by 68
- 2 BRK.B / BRK.A Berkshire Hathaway 2.9% held by 36
- 3 MSFT Microsoft Corp. 2.5% held by 60
- 4 AMZN Amazon Com Inc. 1.9% held by 47
- 5 META Meta Platforms Inc. 1.7% held by 41
- 6 CVNA Carvana Co. 1.4% held by 9
- 7 AAPL Apple Inc. 1.3% held by 34
- 8 V Visa Inc. 0.96% held by 33
- 9 MA Mastercard Inc. 0.76% held by 28
- 10 TSM Taiwan Semiconductor Mfg Ltd 0.75% held by 30
Highest conviction
- 1 CVNA Carvana Co. avg 21.4% held by 9
- 2 HOOD Robinhood Markets Inc. avg 17.9% held by 3
- 3 LOAR Loar Holdings Inc. avg 15.4% held by 3
- 4 CEIXEUR Consol Energy Inc. New avg 13.3% held by 3
- 5 BRK.B / BRK.A Berkshire Hathaway avg 10.6% held by 36
- 6 TDG Transdigm Group Inc. avg 9.9% held by 7
- 7 SNX Td Synnex Corporation avg 9.6% held by 5
- 8 UTHR United Therapeutics Corp. avg 9.6% held by 3
- 9 FICO Fair Isaac Corp. avg 9.2% held by 6
- 10 LBTYK Liberty Global Ltd avg 9.2% held by 3
Did the combined book beat SPY?
Each quarter’s combined book held to the next quarter-end, at the 13Fs’ own prices. Price only, no dividends, and today’s managers throughout. Nobody could have copied it: 13Fs arrive about 45 days after the quarter ends.
Combined book, 8 quarters
+44.2%
SPY
+37.2%
Difference
+6.9 pts
2024 Q2, the start
+0.0% Combined book
+0.0% SPY
2024 Q3, since 2024 Q2
+7.5% Combined book
+5.4% SPY
That quarter: book +7.5%, SPY +5.4%
2024 Q4, since 2024 Q2
+10.2% Combined book
+7.7% SPY
That quarter: book +2.6%, SPY +2.1%
2025 Q1, since 2024 Q2
+6.0% Combined book
+2.8% SPY
That quarter: book −3.8%, SPY −4.6%
2025 Q2, since 2024 Q2
+18.3% Combined book
+13.5% SPY
That quarter: book +11.6%, SPY +10.5%
2025 Q3, since 2024 Q2
+29.0% Combined book
+22.4% SPY
That quarter: book +9.1%, SPY +7.8%
2025 Q4, since 2024 Q2
+31.8% Combined book
+25.3% SPY
That quarter: book +2.1%, SPY +2.4%
2026 Q1, since 2024 Q2
+25.9% Combined book
+19.5% SPY
That quarter: book −4.4%, SPY −4.6%
2026 Q2, since 2024 Q2
+44.2% Combined book
+37.2% SPY
That quarter: book +14.5%, SPY +14.8%
Quarter by quarter
| Quarter | Each manager once | By dollars | SPY | Book − SPY | Managers |
|---|---|---|---|---|---|
| 2026 Q2 | +14.5% | +11.5% | +14.8% | −0.4 pts | 133 |
| 2026 Q1 | −4.4% | −4.2% | −4.6% | +0.2 pts | 136 |
| 2025 Q4 | +2.1% | +2.6% | +2.4% | −0.2 pts | 136 |
| 2025 Q3 | +9.1% | +6.3% | +7.8% | +1.2 pts | 136 |
| 2025 Q2 | +11.6% | +8.0% | +10.5% | +1.1 pts | 136 |
| 2025 Q1 | −3.8% | −2.0% | −4.6% | +0.7 pts | 136 |
| 2024 Q4 | +2.6% | +1.1% | +2.1% | +0.4 pts | 134 |
| 2024 Q3 | +7.5% | +6.9% | +5.4% | +2.1 pts | 133 |
All 2,411 names
Download CSVShowing 300 of 347 matching names. The CSV has every name.
| Ticker | Company | Sector | Held by | Weight | Net bought | Bought / sold | Opened / closed |
|---|---|---|---|---|---|---|---|
| UNH | Unitedhealth Group Inc. | Health Care | 27 −2 | 0.54% | −$1B | 5 / 14 | 2 / 4 |
| DHR | Danaher Corporation | Health Care | 16 | 0.24% | −$86M | 3 / 6 | 1 / 1 |
| JNJ | Johnson & Johnson | Health Care | 16 +1 | 0.19% | −$8M | 4 / 3 | 1 / 0 |
| TMO | Thermo Fisher Scientific Inc. | Health Care | 15 +1 | 0.18% | −$298M | 2 / 6 | 1 / 0 |
| CVS | Cvs Health Corp. | Health Care | 14 | 0.32% | +$497M | 5 / 4 | 1 / 1 |
| MRK | Merck & Co. Inc. | Health Care | 13 −2 | 0.14% | +$294M | 2 / 5 | 1 / 3 |
| ELV | Elevance Health Inc. | Health Care | 12 −2 | 0.33% | −$151M | 2 / 4 | 0 / 2 |
| BMY | Bristol-Myers Squibb Co. | Health Care | 12 +1 | 0.13% | −$2M | 3 / 2 | 1 / 0 |
| LLY | Eli Lilly & Co. | Health Care | 12 +2 | 0.10% | +$42M | 5 / 1 | 2 / 0 |
| HCA | Hca Healthcare Inc. | Health Care | 11 | 0.26% | +$47M | 3 / 4 | 1 / 1 |
| PFE | Pfizer Inc. | Health Care | 11 −1 | 0.12% | −$216M | 3 / 2 | 0 / 1 |
| MDT | Medtronic PLC | Health Care | 10 | 0.10% | −$1B | 2 / 2 | 0 / 0 |
| ABBV | Abbvie Inc. | Health Care | 10 −1 | 0.03% | −$44M | 1 / 4 | 0 / 1 |
| CI | The Cigna Group | Health Care | 9 −2 | 0.18% | −$191M | 2 / 4 | 0 / 2 |
| GEHC | Ge Healthcare Technologies, Inc. | Health Care | 9 | 0.17% | +$131M | 3 / 5 | 1 / 1 |
| THC | Tenet Healthcare Corp. | Health Care | 9 | 0.14% | −$410M | 1 / 4 | 0 / 0 |
| ZTS | Zoetis Inc. | Health Care | 9 +1 | 0.10% | −$90M | 2 / 2 | 1 / 0 |
| TEVA | Teva Pharmaceutical Inds Ltd | Health Care | 9 +1 | 0.06% | +$103M | 3 / 4 | 2 / 1 |
| ABT | Abbott Labs | Health Care | 9 +1 | 0.05% | −$170M | 1 / 2 | 1 / 0 |
| WST | Western Alliance Bancorp | Health Care | 8 +1 | 0.15% | −$53M | 1 / 3 | 1 / 0 |
| ILMN | Illumina Inc. | Health Care | 8 +1 | 0.14% | +$3M | 2 / 2 | 1 / 0 |
| HUM | Humana, Inc. | Health Care | 8 −3 | 0.10% | +$53M | 3 / 5 | 1 / 4 |
| BAX | Baxter International, Inc. | Health Care | 8 | 0.08% | +$680M | 1 / 2 | 0 / 0 |
| ZBH | Zimmer Biomet Holdings, Inc. | Health Care | 8 | 0.07% | +$53M | 2 / 1 | 0 / 0 |
| BSX | Boston Scientific Corp. | Health Care | 8 +1 | 0.07% | +$174M | 3 / 2 | 1 / 0 |
| NVO | Novo-Nordisk A S | Health Care | 8 −2 | 0.04% | −$64M | 1 / 5 | 0 / 2 |
| AMGN | Amgen Inc. | Health Care | 8 | 0.02% | −$59M | 1 / 2 | 0 / 0 |
| NTRA | Natera Inc. | Health Care | 7 −1 | 0.20% | +$243M | 3 / 3 | 0 / 1 |
| SOLV | Solventum Corporation | Health Care | 7 −1 | 0.14% | +$123M | 1 / 3 | 0 / 1 |
| CAH | Cardinal Health Inc. | Health Care | 7 −1 | 0.13% | −$87M | 1 / 3 | 0 / 1 |
| SNY | Sanofi SA | Health Care | 7 | 0.07% | −$51M | 3 / 2 | 1 / 1 |
| BDX | Becton Dickinson & Co. | Health Care | 7 | 0.05% | +$140M | 3 / 0 | 0 / 0 |
| EW | Edwards Lifesciences Corp. | Health Care | 7 +4 | 0.05% | +$22M | 4 / 1 | 4 / 0 |
| REGN | Regeneron Pharmaceuticals, Inc. | Health Care | 7 +1 | 0.02% | −$6M | 2 / 3 | 2 / 1 |
| INSM | Insmed Inc. | Health Care | 6 | 0.16% | −$116M | 2 / 3 | 1 / 1 |
| OSCR | Oscar Health Inc. | Health Care | 6 +1 | 0.12% | −$58M | 1 / 2 | 1 / 0 |
| VTRS | Viatris Inc. | Health Care | 6 +1 | 0.10% | +$70M | 3 / 0 | 1 / 0 |
| GSK | Gsk PLC | Health Care | 6 | 0.10% | −$11M | 2 / 1 | 0 / 0 |
| AVTR | Avantor, Inc. | Health Care | 6 −1 | 0.06% | +$70M | 2 / 3 | 0 / 1 |
| BNTX | Biontech Se | Health Care | 6 +4 | 0.06% | +$23M | 5 / 1 | 4 / 0 |
| ISRG | Intuitive Surgical Inc. | Health Care | 6 −2 | 0.05% | −$199M | 1 / 4 | 0 / 2 |
| DGX | Quest Diagnostics Inc. | Health Care | 6 | 0.04% | −$21M | 2 / 3 | 0 / 0 |
| BIIB | Biogen Inc. | Health Care | 5 | 0.17% | −$14M | 0 / 2 | 0 / 0 |
| BHC | Bausch Health Companies Inc. | Health Care | 5 −1 | 0.14% | −$10M | 1 / 1 | 0 / 1 |
| BMRN | Biomarin Pharmaceutical, Inc. | Health Care | 5 −1 | 0.12% | +$194M | 2 / 3 | 1 / 2 |
| SYK | Stryker Corp. | Health Care | 5 | 0.10% | −$50M | 1 / 1 | 0 / 0 |
| IQV | Iqvia Hldgs Inc. | Health Care | 5 −1 | 0.08% | −$86M | 1 / 2 | 0 / 1 |
| A | Agilent Technologies Inc. | Health Care | 5 −1 | 0.06% | −$239M | 0 / 3 | 0 / 1 |
| CNC | Centene Corp. Del | Health Care | 5 −1 | 0.06% | −$126M | 1 / 2 | 0 / 1 |
| CRL | Charles Riv Labs Intl Inc. | Health Care | 5 | 0.06% | −$11M | 0 / 2 | 0 / 0 |
| FTRE | Fortrea Hldgs Inc. | Health Care | 5 +1 | 0.06% | +$30M | 3 / 2 | 2 / 1 |
| PCVX | Vaxcyte Inc. | Health Care | 5 +1 | 0.03% | −$21M | 3 / 2 | 2 / 1 |
| VEEV | Veeva Sys Inc. | Health Care | 5 −2 | 0.03% | +$3M | 2 / 3 | 0 / 2 |
| TECH | Bio Techne Corp. | Health Care | 5 | 0.02% | −$30M | 2 / 2 | 0 / 0 |
| VRTX | Vertex Pharmaceuticals Inc. | Health Care | 5 +1 | 0.02% | +$47M | 2 / 1 | 1 / 0 |
| NVS | Novartis AG | Health Care | 5 −1 | 0.01% | −$26M | 0 / 2 | 0 / 1 |
| ALGN | Align Technology Inc. | Health Care | 5 | 0.01% | −$1M | 3 / 1 | 0 / 0 |
| IMVT | Immunovant Inc. | Health Care | 5 −1 | <0.01% | −$31M | 1 / 3 | 0 / 1 |
| SGRY | Surgery Partners Inc. | Health Care | 4 | 0.25% | −$65M | 1 / 4 | 1 / 1 |
| MCK | Mckesson Corp. | Health Care | 4 −3 | 0.18% | −$290M | 1 / 3 | 0 / 3 |
| IDXX | Idexx Laboratories Inc. | Health Care | 4 | 0.06% | −$55M | 1 / 1 | 0 / 0 |
| RPRX | Royalty Pharma PLC | Health Care | 4 | 0.06% | +$26M | 2 / 0 | 0 / 0 |
| BIO | Bio Rad Labs Inc. | Health Care | 4 −1 | 0.06% | +$114M | 2 / 1 | 0 / 1 |
| ALKS | Alkermes PLC | Health Care | 4 | 0.05% | −$3M | 0 / 1 | 0 / 0 |
| CYTK | Cytokinetics Inc. | Health Care | 4 −1 | 0.04% | −$8M | 1 / 2 | 0 / 1 |
| SNDX | Syndax Pharmaceuticals Inc. | Health Care | 4 | 0.04% | −$19M | 0 / 2 | 0 / 0 |
| UHS | Universal Hlth Svcs Inc. | Health Care | 4 | 0.04% | −$116M | 1 / 3 | 1 / 1 |
| ASND | Ascendis Pharma A/S | Health Care | 4 +2 | 0.04% | +$44M | 4 / 1 | 3 / 1 |
| ACHC | Acadia Healthcare Company In | Health Care | 4 | 0.04% | +$17M | 1 / 2 | 0 / 0 |
| NBIX | Neurocrine Biosciences, Inc. | Health Care | 4 | 0.04% | −$8M | 0 / 2 | 0 / 0 |
| BHVN | Biohaven Ltd | Health Care | 4 | 0.03% | +$69M | 2 / 1 | 0 / 0 |
| HOLX | Hologic, Inc. | Health Care | 4 +1 | 0.03% | −$12M | 1 / 2 | 1 / 0 |
| GILD | Gilead Sciences, Inc. | Health Care | 4 −1 | 0.03% | −$39M | 0 / 3 | 0 / 1 |
| MEDP | Medpace Holdings Inc. | Health Care | 4 | 0.02% | +$15M | 2 / 1 | 0 / 0 |
| ICLR | Icon PLC | Health Care | 4 | 0.02% | −$3M | 1 / 0 | 0 / 0 |
| INCY | Incyte Corp. | Health Care | 4 +1 | 0.02% | +$13M | 1 / 2 | 1 / 0 |
| RCKT | Rocket Pharmaceuticals Inc. | Health Care | 4 | 0.02% | −$5M | 1 / 2 | 0 / 0 |
| NAMS | Newamsterdam Pharma Company | Health Care | 4 +1 | 0.02% | +$11M | 3 / 0 | 1 / 0 |
| RARE | Ultragenyx Pharmaceutical In | Health Care | 4 +2 | 0.02% | −$9M | 2 / 2 | 2 / 0 |
| URGN | Urogen Pharma Ltd | Health Care | 4 | 0.02% | −$611K | 0 / 1 | 0 / 0 |
| HSIC | Henry Schein Inc. | Health Care | 4 +2 | 0.01% | +$14M | 3 / 0 | 2 / 0 |
| BCYC | Bicycle Therapeutics PLC | Health Care | 4 +1 | <0.01% | +$1M | 1 / 0 | 1 / 0 |
| UTHR | United Therapeutics Corp. | Health Care | 3 −2 | 0.22% | −$127M | 0 / 5 | 0 / 2 |
| NVAX | Novavax Inc. | Health Care | 3 | 0.18% | −$8M | 1 / 2 | 0 / 0 |
| EXEL | Exelixis Inc. | Health Care | 3 | 0.16% | −$54M | 1 / 2 | 0 / 0 |
| JAZZ | Jazz Pharmaceuticals PLC | Health Care | 3 −1 | 0.13% | −$155M | 0 / 2 | 0 / 1 |
| BLCO | Bausch Plus Lomb Corp. | Health Care | 3 +1 | 0.09% | +$14M | 1 / 0 | 1 / 0 |
| RVMD | Revolution Medicines Inc. | Health Care | 3 −1 | 0.07% | +$72M | 1 / 1 | 0 / 1 |
| WAT | Waters Corp. | Health Care | 3 | 0.07% | −$35M | 0 / 1 | 0 / 0 |
| SHC | Sotera Health Co. | Health Care | 3 −2 | 0.06% | −$17M | 0 / 2 | 0 / 2 |
| IONS | Ionis Pharmaceuticals Inc. | Health Care | 3 −2 | 0.05% | −$3M | 0 / 2 | 0 / 2 |
| ALNY | Alnylam Pharmaceuticals, Inc. | Health Care | 3 −1 | 0.04% | −$110M | 0 / 2 | 0 / 1 |
| MTD | Mettler Toledo Ord | Health Care | 3 | 0.04% | −$8M | 0 / 0 | 0 / 0 |
| ROIV | Roivant Sciences Ltd | Health Care | 3 | 0.04% | −$175M | 1 / 2 | 0 / 0 |
| NVST | Envista Holdings Corporation | Health Care | 3 | 0.03% | +$23M | 1 / 0 | 0 / 0 |
| XENE | Xenon Pharmaceuticals Inc. | Health Care | 3 | 0.03% | +$3M | 1 / 0 | 0 / 0 |
| EWTX | Edgewise Therapeutics Inc. | Health Care | 3 | 0.03% | −$3M | 0 / 2 | 0 / 0 |
| LH | Labcorp Holdings Inc. | Health Care | 3 | 0.03% | −$8M | 0 / 1 | 0 / 0 |
| DVA | Davita Inc. | Health Care | 3 −1 | 0.02% | −$19M | 1 / 2 | 0 / 1 |
| DYN | Dyne Therapeutics Inc. | Health Care | 3 +1 | 0.02% | +$21M | 2 / 0 | 1 / 0 |
| PBH | Prestige Consmr Healthcare I | Health Care | 3 | 0.02% | −$5M | 0 / 1 | 0 / 0 |
| BEAM | Beam Therapeutics Inc. | Health Care | 3 | 0.02% | −$20M | 0 / 1 | 0 / 0 |
| CNTA | Centessa Pharmaceuticals PLC | Health Care | 3 +1 | 0.02% | +$47M | 2 / 0 | 1 / 0 |
| GKOS | Glaukos Corp. | Health Care | 3 | 0.02% | +$16M | 1 / 0 | 0 / 0 |
| VKTX | Viking Therapeutics Inc. | Health Care | 3 | 0.02% | −$46M | 0 / 3 | 0 / 0 |
| PRVA | Privia Health Group Inc. | Health Care | 3 −1 | 0.02% | +$27M | 2 / 2 | 0 / 1 |
| NRIX | Nurix Therapeutics Inc. | Health Care | 3 −1 | 0.02% | −$5M | 0 / 1 | 0 / 1 |
| DXCM | Dexcom Inc. | Health Care | 3 −3 | 0.01% | −$118M | 0 / 5 | 0 / 3 |
| AXSM | Axsome Therapeutics Inc. | Health Care | 3 | 0.01% | −$7M | 0 / 1 | 0 / 0 |
| TALK | Talkspace Inc. | Health Care | 3 +1 | 0.01% | +$545K | 1 / 0 | 1 / 0 |
| DNA | Ginkgo Bioworks Holdings Inc. IPO or spin-off | Health Care | 3 +3 | <0.01% | +$40M | 3 / 0 | 3 / 0 |
| CRNX | Crinetics Pharmaceuticals In | Health Care | 3 | <0.01% | +$34M | 1 / 0 | 0 / 0 |
| CDNA | Caredx Inc. | Health Care | 3 | <0.01% | −$96M | 0 / 2 | 0 / 0 |
| Masimo | Masimo Corp. | Health Care | 3 −1 | <0.01% | +$5M | 1 / 1 | 0 / 1 |
| COO | Cooper Cos Inc. | Health Care | 3 +1 | <0.01% | +$19M | 1 / 0 | 1 / 0 |
| ELAN | Elanco Animal Health, Inc. | Health Care | 3 +1 | <0.01% | −$1M | 2 / 0 | 1 / 0 |
| OPCH | Option Care Health Inc. | Health Care | 3 | <0.01% | +$17M | 2 / 2 | 1 / 1 |
| RLMD | Relmada Therapeutics Inc. | Health Care | 3 | <0.01% | −$389K | 0 / 1 | 0 / 0 |
| NUVB | Nuvation Bio Inc. | Health Care | 3 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| PRME | Prime Medicine Inc. | Health Care | 3 | <0.01% | −$2M | 0 / 1 | 0 / 0 |
| Compugen | Compugen Ltd | Health Care | 3 | <0.01% | −$15K | 0 / 0 | 0 / 0 |
| GRFS | Grifols S A | Health Care | 3 | <0.01% | −$3M | 0 / 1 | 0 / 0 |
| MDGL | Madrigal Pharmaceuticals Inc. | Health Care | 2 | 0.21% | +$37M | 1 / 0 | 0 / 0 |
| FOLD | Amicus Therapeutics Inc. | Health Care | 2 | 0.08% | −$9M | 0 / 1 | 0 / 0 |
| OGN | Organon & Company | Health Care | 2 | 0.07% | +$9M | 2 / 0 | 0 / 0 |
| ENTA | Enanta Pharmaceuticals Inc. | Health Care | 2 | 0.07% | +$3M | 1 / 0 | 0 / 0 |
| ALC | Alcon Inc. | Health Care | 2 +1 | 0.06% | −$14M | 1 / 1 | 1 / 0 |
| ARVN | Arvinas Inc. | Health Care | 2 | 0.05% | −$19M | 1 / 1 | 0 / 0 |
| IDYA | Ideaya Biosciences Inc. | Health Care | 2 | 0.04% | +$10M | 2 / 0 | 0 / 0 |
| INDV | Indivior PLC | Health Care | 2 +1 | 0.04% | +$57M | 2 / 0 | 1 / 0 |
| IOVA | Iovance Biotherapeutics Inc. | Health Care | 2 −1 | 0.03% | +$266K | 1 / 1 | 0 / 1 |
| ANAB | Anaptysbio Inc. | Health Care | 2 +1 | 0.03% | +$8M | 2 / 0 | 1 / 0 |
| CRSP | Crispr Therapeutics AG | Health Care | 2 −1 | 0.02% | −$38M | 0 / 1 | 0 / 1 |
| AXGN | Axogen Inc. | Health Care | 2 | 0.02% | $0 | 0 / 0 | 0 / 0 |
| CATX | Perspective Therapeutics Inc. | Health Care | 2 | 0.02% | +$5M | 1 / 0 | 0 / 0 |
| LQDA | Liquidia Corporation | Health Care | 2 | 0.02% | +$26M | 2 / 0 | 0 / 0 |
| IART | Integra Lifesciences Hldgs C | Health Care | 2 +1 | 0.02% | +$45M | 2 / 0 | 1 / 0 |
| BBIO | Bridgebio Pharma Inc. | Health Care | 2 +1 | 0.02% | +$44M | 1 / 0 | 1 / 0 |
| Perrigo | Perrigo Company PLC | Health Care | 2 | 0.02% | +$7M | 2 / 0 | 0 / 0 |
| TWST | Twist Bioscience Corp. | Health Care | 2 | 0.02% | −$28M | 1 / 1 | 0 / 0 |
| PTGX | Protagonist Therapeutics Inc. | Health Care | 2 | 0.02% | +$910K | 0 / 0 | 0 / 0 |
| LNTH | Lantheus Hldgs Inc. | Health Care | 2 −1 | 0.01% | +$41M | 1 / 2 | 0 / 1 |
| MIRM | Mirum Pharmaceuticals Inc. | Health Care | 2 | 0.01% | $0 | 0 / 0 | 0 / 0 |
| VCYT | Veracyte Inc. | Health Care | 2 −1 | 0.01% | −$73M | 0 / 2 | 0 / 1 |
| TRVI | Trevi Therapeutics Inc. | Health Care | 2 | 0.01% | −$257K | 0 / 0 | 0 / 0 |
| LKFT | Galapagos NV | Health Care | 2 | 0.01% | +$7M | 1 / 0 | 0 / 0 |
| ARGX | Argenx Se | Health Care | 2 | 0.01% | −$18M | 0 / 1 | 0 / 0 |
| GPCR | Structure Therapeutics Inc. | Health Care | 2 −1 | <0.01% | −$29M | 1 / 2 | 0 / 1 |
| NVCR | Novocure Ltd | Health Care | 2 | <0.01% | +$494K | 1 / 0 | 0 / 0 |
| KYMR | Kymera Therapeutics Inc. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$25M | 2 / 0 | 2 / 0 |
| NUVL | Nuvalent Inc. | Health Care | 2 +1 | <0.01% | +$16M | 2 / 0 | 1 / 0 |
| FMS | Fresenius Medical Care AG | Health Care | 2 | <0.01% | −$387K | 0 / 0 | 0 / 0 |
| ADPT | Adaptive Biotechnologies Cor | Health Care | 2 | <0.01% | +$968K | 0 / 0 | 0 / 0 |
| VNDA | Vanda Pharmaceuticals Inc. | Health Care | 2 | <0.01% | −$1M | 0 / 1 | 0 / 0 |
| PHG | Koninklijke Philips NV | Health Care | 2 | <0.01% | −$865K | 0 / 1 | 0 / 0 |
| NGNE | Neurogene Inc. | Health Care | 2 | <0.01% | −$13M | 0 / 2 | 0 / 0 |
| LXEO | Lexeo Therapeutics Inc. | Health Care | 2 +1 | <0.01% | +$2M | 1 / 0 | 1 / 0 |
| ORIC | Oric Pharmaceuticals Inc. | Health Care | 2 | <0.01% | +$14M | 1 / 1 | 1 / 1 |
| XRAY | Dentsply Sirona Inc. | Health Care | 2 | <0.01% | +$29M | 1 / 0 | 0 / 0 |
| STOK | Stoke Therapeutics Inc. | Health Care | 2 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| SPRY | Ars Pharmaceuticals Inc. | Health Care | 2 +1 | <0.01% | +$6M | 1 / 1 | 1 / 0 |
| MRNA | Moderna Inc. | Health Care | 2 −1 | <0.01% | +$4M | 1 / 2 | 0 / 1 |
| BTI | British Amern Tob PLC | Health Care | 2 | <0.01% | +$4M | 1 / 0 | 0 / 0 |
| ALLO | Allogene Therapeutics Inc. | Health Care | 2 | <0.01% | +$1M | 1 / 0 | 0 / 0 |
| SDGR | Schrodinger Inc. | Health Care | 2 | <0.01% | −$2M | 0 / 0 | 0 / 0 |
| ITGR | Integer Hldgs Corp. | Health Care | 2 | <0.01% | +$5M | 1 / 0 | 0 / 0 |
| COGT | Cogent Biosciences Inc. | Health Care | 2 | <0.01% | −$4M | 0 / 1 | 0 / 0 |
| LFST | Lifestance Health Group Inc. | Health Care | 2 +1 | <0.01% | −$12M | 1 / 1 | 1 / 0 |
| ALVO | Alvotech SA | Health Care | 2 +1 | <0.01% | +$2M | 1 / 0 | 1 / 0 |
| BFLY | Butterfly Network Inc. | Health Care | 2 | <0.01% | −$685K | 1 / 1 | 0 / 0 |
| CMPS | Compass Pathways PLC | Health Care | 2 | <0.01% | −$601K | 0 / 0 | 0 / 0 |
| ESTA | Establishment Labs Hldgs Inc. | Health Care | 2 | <0.01% | −$13M | 1 / 1 | 0 / 0 |
| NEOG | Neogen Corp. | Health Care | 2 | <0.01% | +$3M | 1 / 0 | 0 / 0 |
| EMBC | Embecta Corp. | Health Care | 2 | <0.01% | −$4M | 0 / 1 | 0 / 0 |
| BKD | Brookdale Sr Living Inc. | Health Care | 2 | <0.01% | −$30M | 1 / 1 | 0 / 0 |
| INSP | Inspire Med Sys Inc. | Health Care | 2 | <0.01% | −$2M | 0 / 0 | 0 / 0 |
| PEPG | Pepgen Inc. | Health Care | 2 +1 | <0.01% | +$2M | 1 / 0 | 1 / 0 |
| ZLAB | Zai Lab Ltd | Health Care | 2 | <0.01% | +$638K | 1 / 0 | 0 / 0 |
| EDIT | Editas Medicine Inc. | Health Care | 2 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| TMDX | Transmedics Group Inc. | Health Care | 2 +1 | <0.01% | +$11M | 2 / 0 | 1 / 0 |
| IVVD | Invivyd Inc. | Health Care | 2 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ANRO | Alto Neuroscience Inc. | Health Care | 2 +1 | <0.01% | +$2M | 1 / 1 | 1 / 0 |
| HIMS | Hims & Hers Health Inc. | Health Care | 2 | <0.01% | +$55K | 1 / 0 | 0 / 0 |
| HQY | Healthequity Inc. | Health Care | 2 | <0.01% | −$4M | 0 / 1 | 0 / 0 |
| GRAL | Grail Inc. | Health Care | 2 −1 | <0.01% | −$6M | 1 / 3 | 1 / 2 |
| ARDT | Ardent Health Partners Inc. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$6M | 2 / 0 | 2 / 0 |
| PGNY | Progyny Inc. | Health Care | 2 | <0.01% | −$6M | 0 / 1 | 0 / 0 |
| RGEN | Repligen Corp. | Health Care | 2 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| EHC | Encompass Health Corp. | Health Care | 2 | <0.01% | −$213K | 0 / 0 | 0 / 0 |
| ENOV | Enovis Corporation | Health Care | 2 | <0.01% | −$9K | 0 / 0 | 0 / 0 |
| RDNT | Radnet Inc. | Health Care | 2 | <0.01% | +$631K | 1 / 0 | 0 / 0 |
| MBX | Mbx Biosciences Inc. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$1M | 2 / 0 | 2 / 0 |
| BCAX | Bicara Therapeutics Inc. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$765K | 2 / 0 | 2 / 0 |
| HROW | Harrow Health Inc. | Health Care | 1 | 0.22% | $0 | 0 / 0 | 0 / 0 |
| AVAH | Aveanna Healthcare Hldgs Inc. | Health Care | 1 | 0.17% | $0 | 0 / 0 | 0 / 0 |
| TGTX | Tg Therapeutics Inc. | Health Care | 1 | 0.07% | $0 | 0 / 0 | 0 / 0 |
| OCUL | Ocular Therapeutix Inc. | Health Care | 1 | 0.05% | −$2M | 0 / 1 | 0 / 0 |
| STXS | Stereotaxis Inc. | Health Care | 1 | 0.05% | $0 | 0 / 0 | 0 / 0 |
| ACAD | Acadia Pharmaceuticals Inc. | Health Care | 1 | 0.04% | +$2M | 0 / 0 | 0 / 0 |
| LFCR | Lifecore Biomedical Inc. | Health Care | 1 | 0.04% | +$62K | 0 / 0 | 0 / 0 |
| RYTM | Rhythm Pharmaceuticals Inc. | Health Care | 1 | 0.03% | −$786K | 0 / 0 | 0 / 0 |
| ATRC | Atricure Inc. | Health Care | 1 | 0.03% | +$70K | 0 / 0 | 0 / 0 |
| WGS | Genedx Holdings Corp. | Health Care | 1 | 0.03% | $0 | 0 / 0 | 0 / 0 |
| DNTH | Dianthus Therapeutics Inc. | Health Care | 1 | 0.03% | $0 | 0 / 0 | 0 / 0 |
| PRTA | Prothena Corp. PLC | Health Care | 1 | 0.03% | +$1M | 0 / 0 | 0 / 0 |
| CGON | Cg Oncology Inc. | Health Care | 1 | 0.02% | +$14M | 1 / 0 | 0 / 0 |
| ETON | Eton Pharmaceuticals Inc. | Health Care | 1 | 0.02% | +$2M | 1 / 0 | 0 / 0 |
| MOH | Molina Healthcare Inc. | Health Care | 1 −1 | 0.02% | +$135M | 1 / 1 | 0 / 1 |
| DOCS | Doximity Inc. | Health Care | 1 −1 | 0.02% | +$65M | 1 / 1 | 0 / 1 |
| TNDM | Tandem Diabetes Care Inc. | Health Care | 1 | 0.02% | $0 | 0 / 0 | 0 / 0 |
| Kalvista Pharmaceutic… | Kalvista Pharmaceuticals Inc. | Health Care | 1 | 0.01% | −$965K | 0 / 1 | 0 / 0 |
| RXRX | Recursion Pharmaceuticals Inc. | Health Care | 1 | 0.01% | +$30M | 1 / 0 | 0 / 0 |
| KURA | Kura Oncology Inc. | Health Care | 1 | 0.01% | −$296K | 0 / 0 | 0 / 0 |
| PHAT | Phathom Pharmaceuticals Inc. | Health Care | 1 | 0.01% | +$3M | 1 / 0 | 0 / 0 |
| WVE | Wave Life Sciences Ltd | Health Care | 1 −1 | 0.01% | +$17M | 1 / 1 | 0 / 1 |
| QDEL | Quidelortho Corp. | Health Care | 1 −1 | 0.01% | −$52M | 0 / 2 | 0 / 1 |
| LIVN | Livanova PLC | Health Care | 1 | <0.01% | −$2M | 0 / 1 | 0 / 0 |
| AGIO | Agios Pharmaceuticals Inc. | Health Care | 1 | <0.01% | +$283K | 0 / 0 | 0 / 0 |
| NMRA | Neumora Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| BCRX | Biocryst Pharmaceuticals Inc. | Health Care | 1 | <0.01% | −$285K | 0 / 1 | 0 / 0 |
| COLL | Collegium Pharmaceutical Inc. | Health Care | 1 −2 | <0.01% | −$6M | 0 / 2 | 0 / 2 |
| XOMA | Xoma Corp. Del | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ALEC | Alector Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ORKA | Oruka Therapeutics Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$19M | 1 / 0 | 1 / 0 |
| SUPN | Supernus Pharmaceuticals, Inc. | Health Care | 1 | <0.01% | +$12K | 0 / 0 | 0 / 0 |
| LZAGY | Lonza Group Adr | Health Care | 1 | <0.01% | −$68K | 0 / 0 | 0 / 0 |
| RCUS | Arcus Biosciences Inc. | Health Care | 1 | <0.01% | +$54K | 0 / 0 | 0 / 0 |
| TERN | Terns Pharmaceuticals Inc. | Health Care | 1 | <0.01% | +$17M | 1 / 1 | 1 / 1 |
| Enhabit | Enhabit Inc. | Health Care | 1 | <0.01% | +$443K | 0 / 0 | 0 / 0 |
| PODD | Insulet Corp. | Health Care | 1 −1 | <0.01% | −$63M | 0 / 1 | 0 / 1 |
| PGEN | Precigen Inc. | Health Care | 1 | <0.01% | −$224K | 0 / 0 | 0 / 0 |
| TFX | Teleflex Incorporated | Health Care | 1 | <0.01% | +$11M | 1 / 0 | 0 / 0 |
| LRMR | Larimar Therapeutics Inc. | Health Care | 1 | <0.01% | −$954K | 0 / 1 | 0 / 0 |
| CNTX | Context Therapeutics Inc. | Health Care | 1 | <0.01% | −$4K | 0 / 0 | 0 / 0 |
| AQST | Aquestive Therapeutics Inc. | Health Care | 1 | <0.01% | +$297K | 1 / 0 | 0 / 0 |
| IPSC | Century Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| MYGN | Myriad Genetics Inc. | Health Care | 1 | <0.01% | −$68M | 0 / 1 | 0 / 0 |
| ZNTL | Zentalis Pharmaceuticals Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$4M | 1 / 0 | 1 / 0 |
| BWAY | Brainsway Ltd | Health Care | 1 | <0.01% | −$428K | 0 / 1 | 0 / 0 |
| ARAY | Accuray Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| INGN | Inogen Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ALHC | Alignment Healthcare Inc. | Health Care | 1 | <0.01% | +$18M | 1 / 0 | 0 / 0 |
| APGE | Apogee Therapeutics Inc. | Health Care | 1 | <0.01% | −$20M | 0 / 1 | 0 / 0 |
| TAK | Takeda Pharmaceutical Co. Ltd | Health Care | 1 | <0.01% | −$1M | 0 / 1 | 0 / 0 |
| ARCT | Arcturus Therapeutics Holdings | Health Care | 1 | <0.01% | +$3M | 1 / 0 | 0 / 0 |
| HALO | Halozyme Therapeutics | Health Care | 1 | <0.01% | +$258K | 1 / 0 | 0 / 0 |
| RMD | Resmed Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$116M | 1 / 0 | 1 / 0 |
| MLYS | Mineralys Therapeutics Inc. | Health Care | 1 | <0.01% | +$333K | 1 / 0 | 0 / 0 |
| AUTL | Autolus Therapeutics PLC | Health Care | 1 | <0.01% | +$508K | 1 / 0 | 0 / 0 |
| PRQR | Proqr Therapeutics N V | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| RZLT | Rezolute Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$2M | 1 / 0 | 1 / 0 |
| Catalyst Pharmaceutic… | Catalyst Pharmaceuticals Inc. | Health Care | 1 | <0.01% | −$10M | 0 / 1 | 0 / 0 |
| CGEM | Cullinan Therapeutics Inc. | Health Care | 1 | <0.01% | −$19M | 0 / 1 | 0 / 0 |
| PSNL | Personalis Inc. | Health Care | 1 | <0.01% | +$4M | 1 / 0 | 0 / 0 |
| ABCL | Abcellera Biologics Inc. | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| COYA | Coya Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| GH | Guardant Health Inc. | Health Care | 1 | <0.01% | +$24M | 1 / 0 | 0 / 0 |
| CERS | Cerus Corp. | Health Care | 1 | <0.01% | −$3M | 0 / 1 | 0 / 0 |
| DMAC | Diamedica Therapeutics Inc. | Health Care | 1 | <0.01% | +$468K | 1 / 0 | 0 / 0 |
| COR | Cencora Inc. | Health Care | 1 −1 | <0.01% | −$2M | 0 / 1 | 0 / 1 |
| PHVS | Pharvaris N V | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ABSI | Absci Corp. | Health Care | 1 | <0.01% | +$3M | 1 / 0 | 0 / 0 |
| TSHA | Taysha Gene Therapies Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| RDY | Dr Reddy's Laboratories Ltd | Health Care | 1 | <0.01% | +$134K | 0 / 0 | 0 / 0 |
| GUTS | Fractyl Health Inc. | Health Care | 1 | <0.01% | −$16K | 0 / 0 | 0 / 0 |
| TVTX | Travere Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| EOLS | Evolus Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| SRTA | Blade Air Mobility Inc. | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| ACRV | Acrivon Therapeutics Inc. | Health Care | 1 | <0.01% | −$63K | 0 / 1 | 0 / 0 |
| QURE | Uniqure NV IPO or spin-off | Health Care | 1 +1 | <0.01% | +$3M | 1 / 0 | 1 / 0 |
| ALDX | Aldeyra Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ADCT | Adc Therapeutics SA | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| OSUR | Orasure Technologies Inc. | Health Care | 1 | <0.01% | −$19K | 0 / 1 | 0 / 0 |
| IBIO | Ibio Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| BDTX | Black Diamond Therapeutics I IPO or spin-off | Health Care | 1 +1 | <0.01% | +$544K | 1 / 0 | 1 / 0 |
| USNA | Usana Health Sciences Inc. | Health Care | 1 | <0.01% | +$3M | 1 / 0 | 0 / 0 |
| INBX | Inhibrx Biosciences Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| VSTM | Verastem Inc. | Health Care | 1 | <0.01% | −$2M | 1 / 1 | 1 / 1 |
| RFL | Rafael Holding | Health Care | 1 | <0.01% | −$2K | 0 / 0 | 0 / 0 |
| APRE | Aprea Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ACRS | Aclaris Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| FHTX | Foghorn Therapeutics Inc. | Health Care | 1 | <0.01% | −$39K | 0 / 1 | 0 / 0 |
| PYXS | Pyxis Oncology Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$624K | 1 / 0 | 1 / 0 |
| CON | Concentra Group Holdings Par IPO or spin-off | Health Care | 1 +1 | <0.01% | +$6M | 1 / 0 | 1 / 0 |
| TECX | Tectonic Therapeutic Inc. | Health Care | 1 | <0.01% | +$3M | 1 / 0 | 0 / 0 |
| VYGR | Voyager Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| CRMD | Cormedix Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| SYRE | Spyre Therapeutics Inc. | Health Care | 1 −2 | <0.01% | −$25M | 0 / 2 | 0 / 2 |
| CMPX | Compass Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ADGM | Adagio Med Hldgs Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$285K | 1 / 0 | 1 / 0 |
| MRVI | Maravai Lifesciences Hldgs I | Health Care | 1 −1 | <0.01% | −$6M | 0 / 1 | 0 / 1 |
| XERS | Xeris Biopharma Holdings Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| GANX | Gain Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| SNN | Smith & Nephew PLC IPO or spin-off | Health Care | 1 +1 | <0.01% | +$2M | 1 / 0 | 1 / 0 |
| AORT | Artivion Inc. | Health Care | 1 | <0.01% | +$631K | 0 / 0 | 0 / 0 |
| HSTM | Healthstream Inc. | Health Care | 1 | <0.01% | +$479K | 0 / 0 | 0 / 0 |
| BIOA | Bioage Labs Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$2M | 1 / 0 | 1 / 0 |
| PNTG | Pennant Group Inc. | Health Care | 1 | <0.01% | −$464K | 0 / 0 | 0 / 0 |
| CRBU | Caribou Biosciences Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| Select Med | Select Med Hldgs Corp. | Health Care | 1 | <0.01% | +$638K | 1 / 0 | 0 / 0 |
How the numbers work
Same managers in both quarters
Changes compare only managers with a 13F in both 2024 Q2 and 2024 Q3: 133 this time. New in 2024 Q3: Rule One Partners.
Buying versus price
Each holding’s dollar change splits into price (what last quarter’s shares earned by this quarter’s 13F price) and net bought (shares added or cut, times this quarter’s price), using each 13F’s own values. The two add back to the change exactly. Stock splits are adjusted first.
Who counts as a buyer or a seller
A manager bought a stock if it opened a position, or added at least 5% to its shares or a trade worth 0.25% of its book; it sold if it closed the position or cut it by the same amounts. Smaller changes count as holding, and a stock split never counts. A manager was a net buyer for the quarter when its trading added up to at least 0.25% of its book. GOOG and GOOGL count once.
IPOs, spin-offs and mergers
A stock no tracked manager held last quarter (an IPO, a spin-off, a new share class) is not counted as buying, and one nobody holds now (a merger, a delisting) is not counted as selling. Choose them under All names to see them.
Each manager once, or by dollars
By default every manager counts the same, so a list leads with what the most managers did. By dollars ranks by money moved and weighs holdings by size, so the largest books set the order.
Sectors
GICS sectors where the company has one. Funds, foreign listings and private shares have none; their buying is shown on its own, never filed under Other. Sector weights are shares of the names that have a sector.
The combined book against SPY
Each quarter-end’s combined book is held to the next quarter-end at the 13Fs’ own prices: price only, no dividends, and today’s featured managers for every quarter. SPY is the same filings’ price for SPY. It is a record of what the managers held, not something anyone could have copied, because 13Fs arrive about 45 days after the quarter ends.
What a 13F leaves out
Long US-listed stock only: no shorts, cash, bonds or foreign listings, and options are left out here.